Update on desmoid tumors

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 562-569

  Escobar, C ^a   Munker, R ^a   Thomas, J O ^a   Li, B D ^b   Burton, G V ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

Aggressive fibromatosis; Desmoid tumors; Diagnosis; Treatment

Indexed keywords

ALPHA2B INTERFERON; ANTHRACYCLINE DERIVATIVE; BETA CATENIN; DOXORUBICIN; IFOSFAMIDE; IMATINIB; INDOMETACIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SULINDAC; TAMOXIFEN; VINCA ALKALOID;

ADENOMATOSIS POLYPOSIS COLI GENE; ADENOMATOUS POLYP; BETA CATENIN GENE; BREAST CANCER; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHROMOSOME ABERRATION; COMPUTER ASSISTED TOMOGRAPHY; DESMOID TUMOR; DISEASE FREE INTERVAL; DRUG DOSE INCREASE; DRUG EFFICACY; FAMILIAL ADENOMATOUS POLYPOSIS; FAMILY HISTORY; FOLLOW UP; GARDNER SYNDROME; GENE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAABDOMINAL DESMOID TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PENETRANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOMYOLYSIS; SOMATIC MUTATION; TUMOR RECURRENCE; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT;

EID: 84863255028     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr386     Document Type: Review

References (64)

1. Müller J. Über den feinen Bau und die Formen der krankhaften Geschwülste. Berlin, Germany: G Reimer 1838; 581-583.
2. Hosalkar HS, Torbert JT, Fox EJ et al. Musculoskeletal desmoid tumors. J Am Acad Orthop Surg 2008; 16: 188-198.
3. Janinis J, Patriki M, Vini L et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003; 14: 181-190.
4. Nuyttens JJ, Rust PF, Thomas et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer 2000; 88: 1517-1523.
5. Bertario L, Russo A, Sala P et al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003; 21: 1698-1707.
6. Hartley JE, Church JM, Gupta S et al. Significance of incidental desmoids identified during surgery for familial adenomatous polyposis. Dis Colon Rectum 2004; 47: 334-338.
7. Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM et al. A nation-wide study comparing sporadic and familial adenomatous polyposis (FAP) related desmoid-type fibromatoses. Int J Cancer 2010; 129: 256-261.
8. Meazza C, Bisogno G, Gronchi A et al. Aggressive fibromatosis in children and adults. Cancer 2010; 116: 233-240.
9. Sinha A, Tekkis PP, Gibbons DC et al. Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis 2010; doi: 10.1111/j.1463-1318.2010.02345.x.
10. Reitamo JJ, Scheinin TM, Häyry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg 1986; 151: 230-237.
11. Wallis YL, Morton DG, McKeown CM et al. Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 1999; 36: 14-20.
12. Iwama T, Kuwabara K, Ushiama M et al. Identification of somatic APC mutations in recurrent desmoid tumors in a patient with familial adenomatous polyposis to determine actual recurrence of the original tumor or de novo occurrence. Fam Cancer 2009; 8: 51-54.
13. Tejpar S, Nollet F, Li C et al. Predominance of beta-catenin mutations and betacatenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999; 18: 6615-6620.
14. Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 2007; 51: 509-514.
15. Lazar AJF, Tuvin D, Hajibashi S et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008; 173: 1518-1527.
16. Domont J, Salas S, Lacroix L et al. High frequency of b-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer 2010; 102: 1032-1036.
17. Amary MF, Pauwels P, Meulemans E et al. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool. Am J Surg Pathol 2007; 31: 1299-1309.
18. Saito T, Oda Y, Tanaka K et al. Beta-catenin nuclear expression correlates with cyclin D1 over-expression in sporadic desmoid tumors. J Pathol 2001; 195: 222-228.
19. Couture J, Mitri A, Lagace R et al. A germ-line mutation at extreme 3' end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of beta-catenin in the desmoid tumor. Clin Genet 2000; 57: 205-212.
20. Salas S, Chibon F, Noguchi T et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer 2010; 49: 560-568.
21. Bacac M, Migliavacca E, Stehle JC et al. A gene expression signature that distinguishes desmoid tumors from nodular fasciitis. J Pathol 2006; 208: 543-553.
22. Gebert C, Hardes J, Kersting C et al. Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis. Histopathology 2007; 50: 491-497.
23. Kotiligam D, Lazar AJF, Pollock RE et al. Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol 2008; 23: 117-126.
24. Lips DJ, Barker N, Clevers H et al. The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors). Eur J Surg Oncol 2009; 35: 3-10.
25. Lazar AJF, Hajibashi S, Lev D. Desmoid tumor: from surgical extirpation to molecular dissection. Curr Opin Oncol 2009; 21: 352-359.
26. Signoroni S, Frattini M, Negri T et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res 2007; 13: 5034.
27. Wu C, Nik Amini S, Nadesan P et al. Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. Cancer Res 2010; 70: 7690-7698.
28. Tjandra SS, Hsu C, Goh I. IFN-b signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors. Cancer Res 2007; 67: 7124-7131.
29. Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer 2006; 106: 208-213.
30. Leithner A, Gapp M, Radl R et al. Immunohistochemical analysis of desmoid tumours. J Clin Pathol 2005; 58: 1152-1156.
31. Santos GA, Cunha IW, Rocha RM et al. Evaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment options. Biosci Trends 2010; 4: 25-30.
32. Matsuo T, Hiyama E, Sugita T et al. Telomere length and telomerase activity in extra-abdominal desmoid tumors. Anticancer Res 2007; 27: 411-416.
33. Cho NL, Carothers AM, Rizvi H et al. Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors. J Surg Res 2011. doi.org/10.1016/j.jss.2010.10.037.
34. Hong H, Nadesan P, Poon R et al. Testosterone regulates cell proliferation in aggressive fibromatosis (desmoid tumor). Br J Cancer 2011; 104: 1452-1458.
35. Zhang ZL, Liang CH, Liu YB et al. Computed tomography and magnetic resonance imaging features of desmoid-type fibromatosis: comparison with the pathological findings. Nan Fang Yi Ke Da Xue Xue Bao 2010; 30: 2495-2497.
36. Guglielmi G, Cifaratti A, Scalzo G et al. Imaging of superficial and deep fibromatosis. Radiol Med 2009; 114: 1292-1307.
37. Kasper B, Dimitrakopoulou-Strauss A, Strauss LG, Hohenberger P. Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib. Eur J Med Mol Imaging 2010; 37: 1876-1882.
38. Ballo MT, Zagars GK, Pollack A et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy or combined surgery and radiation therapy. J Clin Oncol 1999; 17: 158-167.
39. Mankin HJ, Hornicek FJ, Springfield DS. Extra-abdominal desmoid tumors: a report of 234 cases. J Surg Oncol 2010; 102: 380-384.
40. Melis M, Zager JS, Sondak VK. Multimodality management of desmoid tumors: how important is a negative surgical margin? J Surg Oncol 2008; 98: 594-602.
41. Gega M, Yanagi H, Yoshikawa R et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006; 24: 102-105.
42. Bonvalot S, Eldweny H, Haddad V et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008; 34: 462-468.
43. Seow-Choen F. The management of desmoids in patients with familial adenomatous polyposis (FAP). Acta Chir Iugosl 2008; 55: 83-87.
44. Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG et al. Evaluation of management of desmoids tumours associated with familial adenomatous polyposis in Dutch patients. Br J Cancer 2011; 104: 37-42.
45. Gluck I, Griffith KA, Biermann S et al. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 2011; 80: 787-792.
46. National Comprehensive Cancer Network (NCCN). Guidelines for Soft Tissue Sarcomas, Version 1.2011 www.nccn.org (13 March 2011, date last accessed).
47. Lev D, Kotilingam D, Wei C et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007; 25: 1785-1791.
48. de Camargo VP, Keohan ML, D'Adamo DR et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010; 116: 2258-2265.
49. Garbay D, Le Cesne A, Penel N et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol 2012; 23: 182-186.
50. Fiore M, Rimareix F, Mariani L et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009; 16: 2587-2593.
51. Picariello L, Tonelli F, Brandi ML. Selective oestrogen receptor modulators in desmoid tumours. Expert Opin Investig Drugs 2004; 13: 1457-1468.
52. Hansmann A, Adolph C, Vogel T et al. High-dose tamoxifen and sulindac as firstline treatment for desmoid tumors. Cancer 2004; 100: 612-620.
53. Nishida Y, Tsukushi S, Shido Y et al. Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study. J Clin Oncol 2010; 28: e107-e109.
54. Fernberg JO, Brosjö O, Larsson O et al. Interferon-induced remission in aggressive fibromatosis of the lower extremity. Acta Oncol 1999; 38: 971-972.
55. Stengel G, Metze D, Dörflinger B et al. Treatment of extra-abdominal aggressive fibromatosis with pegylated interferon. J Am Acad Dermatol 2008; 59 (Suppl 1): S7-S9.
56. Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol 2006; 24: 11-12.
57. Mace J, Sybil Biermann J, Sondak V et al. Response of extra-abdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002; 95: 2373-2379.
58. Goncxalves A, Monges G, Yang Y et al. Response of a KIT-positive extraabdominal fibromatosis to imatinib mesylate and KIT genetic analysis. J Natl Cancer Inst 2006; 98: 562-563.
59. Heinrich MC, McArthur GA, Demetri GD et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24: 1195-1203.
60. Chugh R, Wathen JK, Patel SR et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 2010; 16: 4884-4891.
61. Dufresne A, Bertucci F, Penel N et al. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer 2010; 103: 482-485.
62. Penel N, Le Cesne A, Bui BN et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2011; 22: 452-457.
63. Kurtz JE, Asmane I, Voegeli AC et al. A V530I mutation in c-KIT exon 10 is associated to imatinib response in extraabdominal aggressive fibromatosis. Sarcoma 2010; 2010: 458156.
64. Gounder MM, Lefkowitz RA, Keohan ML et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011; 17: 4082-4090.